HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care, announced it will host a conference call on Aug. 13 at 4:30 p.m. ET to discuss financial results for the second quarter ended June 30, 2026, and provide updates on its strategy to accelerate global adoption of its ambulatory ECG signal platform. The call will be led by Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, and Chief Financial Officer Timothy Cruickshank, and will include a question-and-answer session following prepared remarks.
HeartBeam is developing the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. The platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence, enabling physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility.
The company has received significant regulatory milestones, including FDA clearance for arrhythmia assessment in December 2024 and for the 12-lead ECG synthesis software in December 2025. HeartBeam holds over 20 issued patents related to its technology. The company's cleared indications for use are available at HeartBeam Indications.
The upcoming call is a key event for investors and the cardiac care industry, as HeartBeam seeks to redefine cardiac health management by moving diagnostics out of clinical settings and into patients' daily lives. The company's strategy focuses on global adoption of its ambulatory ECG platform, which has the potential to improve early detection and monitoring of critical cardiac conditions, reducing the burden on healthcare systems and improving patient outcomes.
For more information on HeartBeam and its latest news, visit the company's newsroom at https://ibn.fm/BEAT.
